Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA

Journal of Endocrinology

Volumn 210, Issue 3, 2011, Pages 369-377

  Zhao, Shuang Xia ^a   Tsui, Shanli ^b   Cheung, Anthony ^a   Douglas, Raymond S ^c   Smith, Terry J ^c   Banga, J Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; COMPLEMENTARY DNA; SOMATOMEDIN C RECEPTOR; THYROTROPIN; THYROTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; FEMALE; FIBROSIS; GENETIC IMMUNIZATION; GRAVES DISEASE; HISTOLOGY; HYPERTHYROIDISM; IN VIVO STUDY; INCIDENCE; MOUSE; NONHUMAN; ORBIT DISEASE; ORBITAL FIBROSIS; PHENOTYPE; PLASMID; PRIORITY JOURNAL; THYROID GLAND;

ANIMALS; AUTOANTIBODIES; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; ELECTROPORATION; FEMALE; FIBROSIS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; ORBIT; PLASMIDS; RECEPTOR, IGF TYPE 1; RECEPTORS, THYROTROPIN;

EID: 80052750626     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0162     Document Type: Article

References (40)

1. Bahn R 2010 Graves' ophthalmopathy. New England Journal of Medicine 362 726-738.
2. Baker G, Mazziotti G, von Ruhland C & Ludgate M 2005 Reevaluating thyrotropin receptor induced mouse models of Graves' disease and ophthalmopathy. Endocrinology 46 835-844.
3. Banga JP, Nielsen CH, Gilbert JA, El Fassi D & Hegedus L 2008 Application of new therapies in Graves' disease and thyroid associated ophthalmopathy: animal models and translation to human clinical trials. Thyroid 18 973-981.
4. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ & Sorisky A 2000 Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. American Journal of Physiology. Cell Physiology 279 C335-C340.
5. Bonifacio E, Yu L, Williams A, Eisenbarth GS, Bingley PJ, Marconina SM, Adler K, Ziegler A, Mueller PW, Schatz DA et al. 2010 Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical Endocrinology and Metabolism 95 3360-3367.
6. Cemazar M, Golzio M, Sersa G, Rols MP & Teissie R 2006 Electricallyassisted nucleic acids delivery to tissues in vivo: where do we stand. Current Pharmaceutical Design 12 3817-3825.
7. Chen CR, Pichurin P, Nagayama Y, Latrofa B, Rapoport B & McLachlan SM 2003 The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. Journal of Clinical Investigation 111 1897-1904.
8. Costagliola S, Many MC, Salmans-Falys M, Vassart G & Ludgate M 1996 Transfer of thyroiditis, with syngeneic spleen-cells sensitized with the human thyrotropin receptor, to naïve BALB/c and NOD mice. Endocrinology 135 4637-4643.
9. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S & Vassart G 2000 Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. Journal of Clinical Investigation 105 803-811.
10. Dagdelen S, Kong YC & Banga JP 2009 Towards better models of Graves' disease. Endocrinology and Metabolism Clinics of North America 38 343-354.
11. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG & Smith TJ 2010 Increased generation of fibrocytes in thyroid-associated ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 95 430-438.
12. Drexhage HA 2006 Are there more than antibodies to the thyroid stimulating hormone receptor than meets the eye in Graves' disease. Endocrinology 147 9-12.
13. Gilbert JA, Gianoukakis AG, Salehi S, Moorhead J, Rao PV, Khan MZ, McGregor AM, Smith TJ & Banga JP 2006 Monoclonal pathogenic antibodies to the TSH receptor in Graves' disease with potent thyroid stimulating activity, but differential blocking activity activate multiple signaling pathways. Journal of Immunology 176 5084-5092.
14. Gopinath B, Musselman R, Beard N, El-Kaissi S, Tani J, Adams CL &Wall JR 2006 Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Clinical Experimental Immunology 145 56-62.
15. Hunt JD, Brown LE & Jackson DC 2001 Antigenic competition. In: Encyclopedia of Life Sciences. John Wiley & Sons.
16. Johnson KT, Ziler B, Thanos M, Carpineteiro A, Schmid KW, Minich W, Gulbins E, Nagayama Y & Eckstein A 2010 Immunization of C57/BL6 and BALb/c with adenoviral TSHR289 causes significant infiltration of orbital tissues with macrophages and T lymphocytes. International Thyroid Congress. Abstract OC-048.
17. Kahaly GJ 2010 The thyrocyte-fibrocyte link: closing the loop in the pathogenesis of Graves' disease. Journal of Clinical Endocrinology and Metabolism 95 62-65.
18. Kaneda T, Honda A, Hakozaki A, Fuse T, Muto A & Yoshida T 2007 An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology 148 2335-2344.
19. Kong YC 2007 Experimental autoimmune thyroiditis in the mouse. Current Protocols in Immunology. Chapter 15, Unit 15. 7.
20. Many MC, Costagliola S, Detrait M, Denef JF, Vassart G & Ludgate M 1999 Development of an animal model of autoimmune thyroid disease. Journal of Immunology 162 4966-4974.
21. McMahon JM, Signori E,Wells KE, Fazio V &Wells DJ 2001 Optimisation of electrotransfer of plasmid into muscle by pretreatment with hyaluronidase - increased expression with reduced muscle damage. Gene Therapy 8 1264-1270.
22. Mizutori Y, Saitoh O, Eguchi K & Nagayama Y 2006 Adenovirus encoding the thyrotropin receptor A-subunit improves the efficacy of dendritic cellinduced Graves' hyperthyroidism in mice. Journal of Autoimmunity 26 32-36.
23. Naik V, Khadavi N, Naik MN, Hwang C, Goldberg RA, Tsirbas A, Smith TJ & Douglas RS 2008 Biologic therapeutics in thyroid associated ophthalmopathy: translating disease mechanisms into therapy. Thyroid 18 967-971.
24. Naik VM, Naik MN, Goldberg RA, Smith TJ & Douglas RS 2010 Immunopathogenesis of thyroid eye disease: emerging paradigms. Survey of Ophthalmology 55 215-226.
25. Niwa H, Yamamura K & Miyazaki J 1991 Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 18 193-200.
26. Paschke R, Elisei R, Vassart G & Ludgate M 1993 Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extraocular muscle. Journal of Endocrinological Investigation 16 329-332.
27. Perros P & Krassas GE 2009 Graves' orbitopathy: a perspective. Nature Reviews. Endocrinology 5 312-318.
28. Pritchard J, Han R, Horst N, Cruikshank WW & Smith TJ 2003 Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. Journal of Immunology 170 6348-6354.
29. Rao PV, Watson PF, Weetman AP, Carayanniotis G & Banga JP 2003 Contrasting activities of thyrotroin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. Endocrinology 144 260-266.
30. Rees Smith B, McLachlan SM& Furmaniak J 1988 Autoantibodies to the thyrotropin receptor. EndocrineReviews 9 106-121.
31. Shimojo N, Kohno Y, Yamaguchi K, Kikuoka S, Hoshioka A, Niimi H, Hirai A, Tamura Y, Saito Y, Kohn LD et al. 1996 Induction of Graves-like disease in mice by immunization wirth fibroblasts transfected with the thyrotropin receptor and a class II molecule. PNAS 93 11074-11079.
32. Smith TJ 2003 The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 36 409-415.
33. Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S et al. 2008 Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid associated ophthalmopathy. Thyroid 18 983-988.
34. Tree TI, Morgenthaler NG, Duhindan N, Hicks KE, Madec AM, Scherbaum WA & Banga JP 2000 Two distantly spaced amino acids in glutamic acid decarboxylase act in concert for maintainance of conformational determinants recognised by heterogeneous autoantibodies in type 1 diabetes. Diabetologia 43 881-889.
35. Tsui S, Naik V, Hoa N, Hwang CJ, Affifiyan NF, Hikim AS, Gianoukakis AG, Douglas RS & Smith TJ 2008 Evidence for an association between thyroid stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. Journal of Immunology 181 4397-4405.
36. Weightman DR, Perros P, Sherif IH & Kendall-Taylor P 1993 Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16 251-257.
37. Wells KE, McMahon J, Foster H, Ferrer A & Wells DJ 2008 Gene delivery to dystrophic muscle. Methods in Molecular Biology 423 421-431.
38. Yamada M, Li AW, West KA, Chang CH & Wall JR 2002 Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropin receptor. Autoimmunity 35 403-413.
39. Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R & Ludgate M 2009 Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts. Journal of Biological Chemistry 284 26447-26455.
40. Ziler B, Johnson KT, Carpineteiro A, Thanos M, Schmid KW, Schott M, Gulbins E & Eckstein A 2010 Genetic immunization of C57/BL6 mice against D633H TSHR causes specific anti-TSHR receptor activity on a cellular level and macrophage infiltration of orbital tissues. International Thyroid Congress 2010. Abstract OC-074.